Search

everythinglearnresearchcommunity

for

Search:↓

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

A 23-year-old man with hair loss, despite using dutasteride, oral minoxidil, and RU58841, is considering bicalutamide for regrowth but is concerned about feminization. Alternatives like topical estrogen, JXL069, and spironolactone are discussed, with suggestions to explore thyroid levels and other potential underlying conditions.

A hair loss treatment protocol involving topical and oral medications such as Minoxidil, RU58841, Finasteride, Dutasteride, Melatonin, Zinc, Vitamin B6, NAC, Caffeine, Biotin, Ginseng, and Semen; other treatments including Microneedling, Laser Helmet, Nizoral shampoo, Scalp Massage and supplements like Vitamin C, Vitamin D, Fish Oil, and Biotin; and the potential side effects of using this protocol.

An update on the use of Pyrilutamide, a new drug for hair loss, which has resulted in no shedding or testicle ache; other users have questioned the science behind this and shared their own experiences with Finasteride, Minoxidil, and microneedling.

Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.

The conversation is about a user trying to fund lab testing for RU58841 to verify its legitimacy, as there are doubts about its effectiveness. Some users express skepticism about RU58841, suggesting alternatives like KX-826.

The conversation discusses using CB0301/Clascoterone as a potential treatment for hair loss, especially for those experiencing side effects from finasteride and dutasteride. The user currently uses oral minoxidil and considers combining it with other treatments like kx826, DHT blocker supplements, and 2% Nizoral shampoo.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

A 26-year-old man with diffuse alopecia is using electric scalp massage, dermastamp, and multivitamins for treatment but is intolerant to finasteride. A dermatologist recommended PRP and mesotherapy with exosomes and dutasteride.

The user is using a combination of finasteride, dutasteride, oral and topical minoxidil, PRP, and stem cell treatments for hair loss. They report slowed shedding and new vellus hairs on the hairline, questioning if they are a strong responder to the treatment.

The user is exploring hair loss treatments in China, currently using finasteride and minoxidil, and is concerned about seborrheic dermatitis. Clinics are recommending selenium sulfide, doxycycline, and mesotherapy ampoules like PT88/PT66 or SP88/SP66, but the user is unsure about their effectiveness.

RU58841 not working for hair loss after 10 months. Concerns about purity of experimental drugs.

People discussed their intense hair loss treatments, including the use of dutasteride, RU58841, minoxidil, tretinoin, essential oils, microneedling, and various topical sprays. Some users reported success with these methods in preventing hair loss and stimulating hair growth.

Topical bicalutamide is discussed as a potential hair loss treatment. Other treatments mentioned include Minoxidil, finasteride, and RU58841.

The user underwent a hair transplant in Boston, initially dissatisfied with the results, but later achieved significant improvement in hair density and natural appearance after consulting a different surgeon. They used finasteride, minoxidil, and low-level laser therapy as part of their treatment.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.

The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.

The post and conversation are about using bimatoprost for hair regrowth, with the user seeking a higher concentration to enhance results. The user also discusses difficulties in sourcing the powder for personal use.

Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.

GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.

Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.